Subjective and Objective Assessment of Edema during Adjuvant Chemotherapy for Breast Cancer Using Taxane-Containing Regimens in a Randomized Controlled Trial: The National Surgical Adjuvant Study of Breast Cancer 02Ohsumi S.a · Shimozuma K.b · Ohashi Y.c · Takeuchi A.c · Suemasu K.d · Kuranami M.e · Ohno S.f · Watanabe T.g
aDepartment of Breast Oncology, NHO Shikoku Cancer Center, Matsuyama, bDepartment of Biomedical Sciences, College of Life Science, Ritsumeikan University, Kusatsu, cDepartment of Biostatistics, School of Public Health, University of Tokyo, Tokyo, dArche Clinic, Saitama, eDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, fDepartment of Breast Oncology, NHO Kyushu Cancer Center, Fukuoka, and gHamamatsu Oncology Center, Hamamatsu, Japan
Objective: To elucidate the time course of taxane-induced edema which may affect the patients’ quality of life (QOL). Patients and Methods: Our study included the first 300 Japanese patients assigned to 1 of 4 regimens using docetaxel (DTX) or paclitaxel (PTX) by 1:1:1:1 in a randomized controlled trial to evaluate the efficacy of adjuvant therapies for node-positive breast cancer. Patients’ QOL was prospectively assessed by the Functional Assessment of Cancer Therapy (FACT)-breast and -taxane (FACT-T) subscale. The scores of FACT items regarding edema and body weight were used as indicators of edema. Results: The scores for ‘anasarca’, ‘edema of the hands’ and ‘edema of the legs and feet’ of the FACT-T subscale worsened up to 1–2 months after chemotherapy, and body weights increased remarkably until cycle 8 in patients treated with DTX alone (75 mg/m2, 8 cycles, every 3 weeks). Edema-related symptoms and body weight were relatively stable in the other treatment groups. There were statistically significant differences in the scores of those items and in the changes of body weight both between the DTX-alone group and the other three groups combined, and between the groups using DTX and those using PTX. Conclusion: Many patients receiving DTX for >4 cycles suffered significantly from edema.
© 2012 S. Karger AG, Basel
The results of this study were presented at the 32nd Annual San Antonio Breast Cancer Symposium (San Antonio, Tex., USA, December 10–14, 2009).
Received: October 30, 2011
Accepted after revision: January 3, 2012
Published online: March 15, 2012
Number of Print Pages : 8
Number of Figures : 6, Number of Tables : 2, Number of References : 31
Oncology (International Journal for Cancer Research and Treatment)
Vol. 82, No. 3, Year 2012 (Cover Date: April 2012)
Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 0030-2414 (Print), eISSN: 1423-0232 (Online)
For additional information: http://www.karger.com/OCL